Antifungal noted in National Comprehensive Cancer Network guidelines
Posaconazole oral suspension (Noxafil, Schering-Plough) has been added to the National Comprehensive Cancer Network?s (NCCN) recommendations for the prevention of invasive fungal infections that can occur in high-risk cancer patients.
Posaconazole oral suspension (Noxafil, Schering-Plough) has been added to the National Comprehensive Cancer Network's (NCCN) recommendations for the prevention of invasive fungal infections that can occur in high-risk cancer patients. The guideline, Clinical Practice Guidelines in Oncology for Prevention and Treatment of Infections in Patients with Cancer, was recently updated by NCCN and presented during its 12th annual meeting held this month in Hollywood, Fla. Posaconazole was approved in September 2006 for the prevention of invasive Aspergillus and Candida infections in patients 13 years of age and older who are at risk due to being severely immunocompromised. The revised guidelines focus on the importance of antifungal prophylaxis as a strategy for managing patients at high risk for invasive fungal infections. The new guide can be found at
